The latest update on Curis centers on a refreshed price target that holds fair value at US$14.00 while reshaping the story behind how that figure is reached. Analysts have adjusted the model inputs ...
Curis Inc. (ISIN US2312691006) is a clinical-stage biotechnology company developing targeted therapies for cancer, with its ...
LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and ...
Curis Lifesciences Limited is entering a new phase of growth as it expands across domestic branded pharmaceuticals, ...
Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass., Aug. 1, 2024 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of ...
LEXINGTON, Mass., April 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, is pleased to ...
Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected ...
LEXINGTON, Mass., Dec. 9, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the ...
A Curis clinical trial under a partial FDA hold for more than a year is now cleared to resume, and the biotech is working with clinical sites to enroll patients whose blood cancers exhibits certain ...
LEXINGTON, Mass., Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule ...
Curis, a microcap biotech company, is focusing on the development of cancer drugs, currently supporting six drug trials with a burn rate of over $30 million per year. Despite a recent direct offering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results